phenylalanylglutamate: RN given refers to all L-isomer [Medical Subject Headings (MeSH), National Library of Medicine, extracted Dec-2023]
Phe-Glu : A dipeptide formed from L-phenylalanine and L-glutamic acid residues. [Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res]
| ID Source | ID |
|---|---|
| PubMed CID | 151134 |
| CHEMBL ID | 476830 |
| CHEBI ID | 74712 |
| SCHEMBL ID | 3048911 |
| MeSH ID | M0122714 |
| Synonym |
|---|
| phenylalanylglutamate |
| (2s)-2-[[(2s)-2-amino-3-phenylpropanoyl]amino]pentanedioic acid |
| CHEMBL476830 |
| chebi:74712 , |
| 3617-45-6 |
| phe-glu |
| l-glutamic acid, n-l-phenylalanyl- |
| AKOS010407206 |
| n-l-phenylalanyl-l-glutamic acid |
| l-phenylalanyl-l-glutamic acid |
| phenylalanylglutamic acid |
| l-phe-l-glu |
| h-phe-glu-oh |
| SCHEMBL3048911 |
| DTXSID70189735 |
| mfcd00037300 |
| l-phenylalanyl-l-glutamate |
| phenylalanine-glutamate dipeptide |
| phenylalanine glutamate dipeptide |
| fe dipeptide |
| f-e dipeptide |
| phenylalanyl-glutamic acid |
| Q27144851 |
| l-glutamic acid, l-phenylalanyl- |
| (2s)-2-[(2s)-2-amino-3-phenylpropanamido]pentanedioic acid |
| (s)-2-((s)-2-amino-3-phenylpropanamido)pentanedioic acid |
| Role | Description |
|---|---|
| metabolite | Any intermediate or product resulting from metabolism. The term 'metabolite' subsumes the classes commonly known as primary and secondary metabolites. |
| [role information is derived from Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res] | |
| Class | Description |
|---|---|
| dipeptide | Any molecule that contains two amino-acid residues connected by peptide linkages. |
| [compound class information is derived from Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res] | |
| Assay ID | Title | Year | Journal | Article |
|---|---|---|---|---|
| AID396056 | Antagonist activity at human PPARgamma receptor expressed in Saccharomyces cerevisiae AH109 co-transfected with mouse CBP assessed as inhibition of rosiglitazone-induced LBD-CBP interaction at 10 uM by alpha-galactosidase based yeast two hybrid assay | 2008 | European journal of medicinal chemistry, Dec, Volume: 43, Issue:12 | Tryptophan-containing dipeptide derivatives as potent PPARgamma antagonists: design, synthesis, biological evaluation, and molecular modeling. |
| [information is prepared from bioassay data collected from National Library of Medicine (NLM), extracted Dec-2023] | ||||
| Timeframe | Studies, This Drug (%) | All Drugs % |
|---|---|---|
| pre-1990 | 3 (60.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 1 (20.00) | 29.6817 |
| 2010's | 1 (20.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| [information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023] | ||
According to the monthly volume, diversity, and competition of internet searches for this compound, as well the volume and growth of publications, there is estimated to be weak demand-to-supply ratio for research on this compound.
| This Compound (12.53) All Compounds (24.57) |
| Publication Type | This drug (%) | All Drugs (%) |
|---|---|---|
| Trials | 0 (0.00%) | 5.53% |
| Reviews | 0 (0.00%) | 6.00% |
| Case Studies | 0 (0.00%) | 4.05% |
| Observational | 0 (0.00%) | 0.25% |
| Other | 5 (100.00%) | 84.16% |
| [information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023] | ||